Published in J Immunol on October 01, 2012
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Complement inhibition in cancer therapy. Semin Immunol (2013) 1.20
Autocrine effects of tumor-derived complement. Cell Rep (2014) 1.16
The role of complement in tumor growth. Adv Exp Med Biol (2014) 1.11
Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep (2014) 1.01
Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration. J Biol Chem (2015) 0.98
Complement activation promotes colitis-associated carcinogenesis through activating intestinal IL-1β/IL-17A axis. Mucosal Immunol (2015) 0.93
Investigation of complement activation product c4d as a diagnostic and prognostic biomarker for lung cancer. J Natl Cancer Inst (2013) 0.88
Regulation of complement-dependent cytotoxicity by TGF-β-induced epithelial-mesenchymal transition. Oncogene (2015) 0.82
C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat Commun (2016) 0.81
Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice. Oncoimmunology (2013) 0.81
Complement anaphylatoxins as immune regulators in cancer. Cancer Med (2014) 0.79
Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discov (2016) 0.78
Critical role of the C5a-activated neutrophils in high-fat diet-induced vascular inflammation. Sci Rep (2016) 0.78
Complement and macrophage crosstalk during process of angiogenesis in tumor progression. J Biomed Sci (2015) 0.78
Complement factor H in host defense and immune evasion. Cell Mol Life Sci (2016) 0.78
Suppression of Ehrlich carcinoma growth by cobra venom factor. Dokl Biol Sci (2016) 0.77
Activation of the complement cascade enhances motility of leukemic cells by downregulating expression of HO-1. Leukemia (2016) 0.77
High Level of Anaphylatoxin C5a Predicts Poor Clinical Outcome in Patients with Clear Cell Renal Cell Carcinoma. Sci Rep (2016) 0.77
Immunological effects and therapeutic role of C5a in cancer. Expert Rev Clin Immunol (2014) 0.77
Identification of Serum Peptidome Signatures of Non-Small Cell Lung Cancer. Int J Mol Sci (2016) 0.76
Tumor-associated mesenchymal stem-like cells provide extracellular signaling cue for invasiveness of glioblastoma cells. Oncotarget (2016) 0.76
High-Fat Diet-Induced Complement Activation Mediates Intestinal Inflammation and Neoplasia, Independent of Obesity. Mol Cancer Res (2016) 0.75
The High Prevalence of Functional Complement Defects Induced by Chemotherapy. Front Immunol (2016) 0.75
Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells. Int J Mol Sci (2017) 0.75
Evasion and interactions of the humoral innate immune response in pathogen invasion, autoimmune disease, and cancer. Clin Immunol (2015) 0.75
Enrichment of C5a-C5aR axis predicts poor postoperative prognosis of patients with clear cell renal cell carcinoma. Oncotarget (2016) 0.75
Complement C5a induces PD-L1 expression and acts in synergy with LPS through Erk1/2 and JNK signaling pathways. Sci Rep (2016) 0.75
Complement regulatory proteins CFHR1 and CFHR3 and patient response to anti-CD20 monoclonal antibody therapy. Clin Cancer Res (2016) 0.75
Complement component 7 (C7), a potential tumor suppressor, is correlated with tumor progression and prognosis. Oncotarget (2016) 0.75
C5a receptor expression is associated with poor prognosis in urothelial cell carcinoma patients treated with radical cystectomy or nephroureterectomy. Oncol Lett (2016) 0.75
Complement Membrane Attack and Tumorigenesis: A SYSTEMS BIOLOGY APPROACH. J Biol Chem (2016) 0.75
Elevated levels of the complement activation product C4d in bronchial fluids for the diagnosis of lung cancer. PLoS One (2015) 0.75
The dual role of complement in cancer and its implication in anti-tumor therapy. Ann Transl Med (2016) 0.75
The role of the complement system in cancer. J Clin Invest (2017) 0.75
Local endothelial complement activation reverses endothelial quiescence, enabling t-cell homing, and tumor control during t-cell immunotherapy. Oncoimmunology (2017) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol (2009) 25.96
Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med (2002) 23.42
Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. J Exp Med (2000) 16.09
Complement. First of two parts. N Engl J Med (2001) 11.16
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol (2009) 9.41
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res (2004) 4.65
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Role of LAG-3 in regulatory T cells. Immunity (2004) 4.36
Role of laminin and basement membrane in the morphological differentiation of human endothelial cells into capillary-like structures. J Cell Biol (1988) 4.33
MEROPS: the peptidase database. Nucleic Acids Res (2007) 4.32
B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma. J Exp Med (2006) 3.75
Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res (2006) 3.45
FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. Trends Pharmacol Sci (2001) 3.42
Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity (2008) 3.36
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
The role of the anaphylatoxins in health and disease. Mol Immunol (2009) 2.95
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 2.48
Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem (1999) 2.33
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Altered immune responses in interleukin 10 transgenic mice. J Exp Med (1997) 1.85
An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci U S A (2001) 1.85
The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol (2011) 1.82
Activation of the lectin pathway by natural IgM in a model of ischemia/reperfusion injury. J Immunol (2006) 1.78
Generation of C5a by phagocytic cells. Am J Pathol (2002) 1.72
Mannan-binding lectin activates C3 and the alternative complement pathway without involvement of C2. J Clin Invest (2006) 1.69
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
Cancer and the complement cascade. Mol Cancer Res (2010) 1.64
Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol (2000) 1.49
Persistent complement activation on tumor cells in breast cancer. Am J Pathol (1992) 1.48
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (2012) 1.39
Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol (1996) 1.36
C5a-induced gene expression in human umbilical vein endothelial cells. Am J Pathol (2004) 1.34
Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. Chest (2000) 1.32
Ascitic complement system in ovarian cancer. Br J Cancer (2005) 1.30
Tumor microenvironment is multifaceted. Cancer Metastasis Rev (2011) 1.28
CTLA-4: a key regulatory point in the control of autoimmune disease. Immunol Rev (2008) 1.28
Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res (2004) 1.19
Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance. Clin Exp Immunol (1998) 1.16
Complement c3a and c5a induce different signal transduction cascades in endothelial cells. J Immunol (2002) 1.15
Regulatory T cells and immune tolerance to tumors. Immunol Res (2010) 1.15
Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med (1983) 1.13
Down-regulation of human complement factor H sensitizes non-small cell lung cancer cells to complement attack and reduces in vivo tumor growth. J Immunol (2007) 1.11
C3a and C5a enhance granulocyte adhesion to endothelial and epithelial cell monolayers: epithelial and endothelial priming is required for C3a-induced eosinophil adhesion. Immunopharmacology (2000) 1.03
Non-small cell lung cancer cells produce a functional set of complement factor I and its soluble cofactors. Mol Immunol (2007) 1.02
Efficient osteoclast differentiation requires local complement activation. Blood (2010) 1.02
Protection of thyroid cancer cells by complement-regulatory factors. Cancer (1994) 1.00
The complement system in tumor immunity: significance of elevated levels of complement in tumor bearing hosts. Ann N Y Acad Sci (1976) 0.98
C5a promotes migration, proliferation, and vessel formation in endothelial cells. Inflamm Res (2010) 0.96
Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens. BMC Mol Biol (2008) 0.95
Expression of trypsin in human cancer cell lines and cancer tissues and its tight binding to soluble form of Alzheimer amyloid precursor protein in culture. J Biochem (1999) 0.94
Inhibition of urokinase activity reduces primary tumor growth and metastasis formation in a murine lung carcinoma model. Am J Respir Crit Care Med (2010) 0.93
The plasmin cascade and matrix metalloproteinases in non-small cell lung cancer. Thorax (1999) 0.90
Tumour-associated macrophages in nonsmall cell lung cancer: the role of interleukin-10. Eur Respir J (2007) 0.80
Reaction of antithrombin with proteases. Nature of the reaction with trypsin. Biochemistry (1982) 0.80
Effects of C5a and FMLP on interleukin-8 production and proliferation of human umbilical vein endothelial cells. Inflammation (2001) 0.77
Complement: a key system for immune surveillance and homeostasis. Nat Immunol (2010) 10.37
The classical complement cascade mediates CNS synapse elimination. Cell (2007) 9.06
A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A (2008) 7.14
Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med (2006) 5.26
Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe (2011) 5.06
Modulation of the antitumor immune response by complement. Nat Immunol (2008) 4.53
Membranoproliferative glomerulonephritis type II (dense deposit disease): an update. J Am Soc Nephrol (2005) 3.57
Drusen complement components C3a and C5a promote choroidal neovascularization. Proc Natl Acad Sci U S A (2006) 3.25
Complement-targeted therapeutics. Nat Biotechnol (2007) 3.24
Structure of C3b reveals conformational changes that underlie complement activity. Nature (2006) 3.22
The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol (2007) 3.12
Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines. Hum Mutat (2008) 3.02
New approaches to the treatment of dense deposit disease. J Am Soc Nephrol (2007) 3.02
Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A (2002) 2.76
Regulation of Toll-like receptor-mediated inflammatory response by complement in vivo. Blood (2007) 2.72
Essential role of the C5a receptor in E coli-induced oxidative burst and phagocytosis revealed by a novel lepirudin-based human whole blood model of inflammation. Blood (2002) 2.62
Structure of complement fragment C3b-factor H and implications for host protection by complement regulators. Nat Immunol (2009) 2.54
Complement and coagulation: strangers or partners in crime? Trends Immunol (2007) 2.48
Alternative splicing: an emerging topic in molecular and clinical oncology. Lancet Oncol (2007) 2.46
Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest (2003) 2.39
The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med (2003) 2.38
A high-fat diet impairs liver regeneration in C57BL/6 mice through overexpression of the NF-kappaB inhibitor, IkappaBalpha. Hepatology (2005) 2.18
A regulatory role for the C5a anaphylatoxin in type 2 immunity in asthma. J Clin Invest (2006) 2.15
A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol (2006) 2.13
Molecular intercommunication between the complement and coagulation systems. J Immunol (2010) 2.12
Complement in immune and inflammatory disorders: pathophysiological mechanisms. J Immunol (2013) 2.10
The complement inhibitory protein DAF (CD55) suppresses T cell immunity in vivo. J Exp Med (2005) 2.09
Complement-mediated inhibition of neovascularization reveals a point of convergence between innate immunity and angiogenesis. Blood (2010) 2.08
Microbial manipulation of receptor crosstalk in innate immunity. Nat Rev Immunol (2011) 2.01
Protective effects of IL-6 blockade in sepsis are linked to reduced C5a receptor expression. J Immunol (2003) 2.00
Structural and functional implications of the alternative complement pathway C3 convertase stabilized by a staphylococcal inhibitor. Nat Immunol (2009) 1.98
A structural basis for complement inhibition by Staphylococcus aureus. Nat Immunol (2007) 1.95
The HIF-1α hypoxia response in tumor-infiltrating T lymphocytes induces functional CD137 (4-1BB) for immunotherapy. Cancer Discov (2012) 1.95
Direct effects of type I interferons on cells of the immune system. Clin Cancer Res (2011) 1.91
Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal (2010) 1.91
Platelets contribute to the pathogenesis of experimental autoimmune encephalomyelitis. Circ Res (2012) 1.85
MAX inactivation in small cell lung cancer disrupts MYC-SWI/SNF programs and is synthetic lethal with BRG1. Cancer Discov (2013) 1.85
Crosstalk pathways between Toll-like receptors and the complement system. Trends Immunol (2010) 1.83
Increased C5a receptor expression in sepsis. J Clin Invest (2002) 1.79
Hydrophobic effect and hydrogen bonds account for the improved activity of a complement inhibitor, compstatin. J Med Chem (2006) 1.72
Structure of compstatin in complex with complement component C3c reveals a new mechanism of complement inhibition. J Biol Chem (2007) 1.71
Functional receptor for C3a anaphylatoxin is expressed by normal hematopoietic stem/progenitor cells, and C3a enhances their homing-related responses to SDF-1. Blood (2003) 1.68
The role of complement in biomaterial-induced inflammation. Mol Immunol (2006) 1.67
Leptin enhances the recruitment of endothelial progenitor cells into neointimal lesions after vascular injury by promoting integrin-mediated adhesion. Circ Res (2008) 1.66
Compstatin: a complement inhibitor on its way to clinical application. Adv Exp Med Biol (2008) 1.66
Trial of complete weaning from immunosuppression for liver transplant recipients: factors predictive of tolerance. Liver Transpl (2013) 1.66
Interaction between the coagulation and complement system. Adv Exp Med Biol (2008) 1.65
The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol (2010) 1.64
Complement in immune and inflammatory disorders: therapeutic interventions. J Immunol (2013) 1.64
CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination. J Immunol (2003) 1.61
Structures of C3b in complex with factors B and D give insight into complement convertase formation. Science (2010) 1.59
Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin. Virology (2004) 1.58
Complement inhibition decreases the procoagulant response and confers organ protection in a baboon model of Escherichia coli sepsis. Blood (2010) 1.56
Complement component 3 is required for optimal expansion of CD8 T cells during a systemic viral infection. J Immunol (2003) 1.56
Improving selection criteria for lung cancer screening. The potential role of emphysema. Am J Respir Crit Care Med (2015) 1.55
Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria. Blood (2014) 1.55
Complement fragment C3a controls mutual cell attraction during collective cell migration. Dev Cell (2011) 1.54
Human genetic deficiencies reveal the roles of complement in the inflammatory network: lessons from nature. Proc Natl Acad Sci U S A (2009) 1.53
Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol (2002) 1.53
Diet-induced hepatocellular carcinoma in genetically predisposed mice. Hum Mol Genet (2009) 1.52
SPACE: an algorithm to predict and quantify alternatively spliced isoforms using microarrays. Genome Biol (2008) 1.52
Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol (2002) 1.51
Novel and natural knockout lung cancer cell lines for the LKB1/STK11 tumor suppressor gene. Oncogene (2004) 1.49
C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol (2004) 1.48
A prognostic DNA methylation signature for stage I non-small-cell lung cancer. J Clin Oncol (2013) 1.47
Ceruloplasmin/hephaestin knockout mice model morphologic and molecular features of AMD. Invest Ophthalmol Vis Sci (2008) 1.47
Interactions between coagulation and complement--their role in inflammation. Semin Immunopathol (2011) 1.46
C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/reperfusion. J Immunol (2007) 1.45
Interaction with FcγRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol (2011) 1.44
Protection of innate immunity by C5aR antagonist in septic mice. FASEB J (2002) 1.44
Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood (2010) 1.44
Complement in inflammatory tissue damage and disease. Trends Immunol (2002) 1.43
New analogs of the clinical complement inhibitor compstatin with subnanomolar affinity and enhanced pharmacokinetic properties. Immunobiology (2012) 1.39
[Early detection of lung cancer: the right time]. Med Clin (Barc) (2002) 1.39
Inhibition of collagen receptor discoidin domain receptor-1 (DDR1) reduces cell survival, homing, and colonization in lung cancer bone metastasis. Clin Cancer Res (2012) 1.39
Allosteric inhibition of complement function by a staphylococcal immune evasion protein. Proc Natl Acad Sci U S A (2010) 1.37
Complement C5a receptor is essential for the optimal generation of antiviral CD8+ T cell responses. J Immunol (2004) 1.36
Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J Immunol (2012) 1.35
Is complement good or bad for cancer patients? A new perspective on an old dilemma. Trends Immunol (2009) 1.33
Vaccine-induced early control of hepatitis C virus infection in chimpanzees fails to impact on hepatic PD-1 and chronicity. Hepatology (2007) 1.32
Characterization of Ehp, a secreted complement inhibitory protein from Staphylococcus aureus. J Biol Chem (2007) 1.32
Novel monoclonal antibodies against mouse C3 interfering with complement activation: description of fine specificity and applications to various immunoassays. Mol Immunol (2004) 1.32
Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: implications for pre-mRNA processing. Mol Carcinog (2004) 1.32
Pigment epithelium-derived factor in the monkey retinal pigment epithelium and interphotoreceptor matrix: apical secretion and distribution. Exp Eye Res (2004) 1.29
Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. J Neuroimmunol (2004) 1.29
Upregulation of indoleamine 2,3-dioxygenase in hepatitis C virus infection. J Virol (2007) 1.29
Complement: more than a 'guard' against invading pathogens? Trends Immunol (2002) 1.28
Can cells and biomaterials in therapeutic medicine be shielded from innate immune recognition? Trends Immunol (2010) 1.28
Design and NMR characterization of active analogues of compstatin containing non-natural amino acids. J Med Chem (2005) 1.28